Cell-based assay innovation is reshaping how we discover, validate, and de-risk therapeutic candidates across disease areas. This Research Topic invites ...

As we age, our ability to maintain healthy blood and a strong immune system gradually declines, largely because hematopoietic stem cells (HSCs), the ...

CareDx shares rose over 8% in extended trading on Wednesday after the precision medicine company said it will divest its Lab Products business to EuroBio Scientific for cash consi ...

Cambridge-based life sciences specialist Lightcast has raised $27 million from global backers to swell its total funding to ...

Proceeds will help enhance workflows and expand single-cell functional assay portfolio * Brad Crutchfield joins as advisor to support early access ...

DNADX high scores predicted improved PFS, supporting genomic instability and DNA repair deficiency as biologically relevant ...

This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...

Semarion, which combines materials engineering and cell biology to tackle unmet drug screening needs, has raised £3.8million ...

Understanding the differences between biochemical and cell-based assays is key to choosing the right high-throughput ...

DeepCyte, a techbio company building AI toxicology tools for drug development, launched today with $1.5 million in seed funding. The company is introducing two solutions to help biopharma teams detect ...

NIPCR utilises a sophisticated dual approach to research namely utilizing animal models that closely mirror human physiology for high-fidelity data, integrating ‘New Approach Me ...

Proceeds will help enhance workflows and expand single-cell functional assay portfolio -- Brad Crutchfield joins as advisor to support early access growth and upcoming global launch CAMBRIDGE, England ...